Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Persistence of cytomegalovirus in mononuclear cells in peripheral blood from blood donors.

Literature DB >> 2555001

Persistence of cytomegalovirus in mononuclear cells in peripheral blood from blood donors.

P Stanier¹, D L Taylor, A D Kitchen, N Wales, Y Tryhorn, A S Tyms.

Abstract

Mesh：

Substances：
DNA, Viral

Year: 1989 PMID： 2555001 PMCID： PMC1837740 DOI： 10.1136/bmj.299.6704.897

Source DB: PubMed Journal: BMJ ISSN： 0959-8138

× No keyword cloud information.

5 in total

1. The risk of transmitting cytomegalovirus to patients receiving blood transfusions.

Authors: J A Wilhelm; L Matter; K Schopfer
Journal: J Infect Dis Date: 1986-07 Impact factor: 5.226

2. Primer-directed enzymatic amplification of DNA with a thermostable DNA polymerase.

Authors: R K Saiki; D H Gelfand; S Stoffel; S J Scharf; R Higuchi; G T Horn; K B Mullis; H A Erlich
Journal: Science Date: 1988-01-29 Impact factor: 47.728

3. Avoiding false positives with PCR.

Authors: S Kwok; R Higuchi
Journal: Nature Date: 1989-05-18 Impact factor: 49.962

4. Structural analysis of the major immediate early gene of human cytomegalovirus.

Authors: R M Stenberg; D R Thomsen; M F Stinski
Journal: J Virol Date: 1984-01 Impact factor: 5.103

5. Prevention of transfusion-acquired cytomegalovirus infections in newborn infants.

Authors: A S Yeager; F C Grumet; E B Hafleigh; A M Arvin; J S Bradley; C G Prober
Journal: J Pediatr Date: 1981-02 Impact factor: 4.406

5 in total

32 in total

1. Quantitative analysis of latent human cytomegalovirus.

Authors: B Slobedman; E S Mocarski
Journal: J Virol Date: 1999-06 Impact factor: 5.103

2. Human cytomegalovirus latency-associated protein pORF94 is dispensable for productive and latent infection.

Authors: K L White; B Slobedman; E S Mocarski
Journal: J Virol Date: 2000-10 Impact factor: 5.103

3. Detection of cytomegalovirus in urine samples by an enzyme-linked immunosorbent assay using a monoclonal antibody against the viral 150-kilodalton protein.

Authors: T Yamanaka; K Kiyotani; T Sakaguchi; Y Fukuda; K Dohi; M Yamada; M Yoshida; S Nii; T Yoshida
Journal: J Clin Microbiol Date: 1992-03 Impact factor: 5.948

4. Experimental human cytomegalovirus latency in CD14+ monocytes.

Authors: Danna Hargett; Thomas E Shenk
Journal: Proc Natl Acad Sci U S A Date: 2010-11-01 Impact factor: 11.205

5. Human cytomegalovirus replicates abortively in polymorphonuclear leukocytes after transfer from infected endothelial cells via transient microfusion events.

Authors: G Gerna; E Percivalle; F Baldanti; S Sozzani; P Lanzarini; E Genini; D Lilleri; M G Revello
Journal: J Virol Date: 2000-06 Impact factor: 5.103

Persistence of cytomegalovirus in mononuclear cells in peripheral blood from blood donors.

1. The risk of transmitting cytomegalovirus to patients receiving blood transfusions.

2. Primer-directed enzymatic amplification of DNA with a thermostable DNA polymerase.

3. Avoiding false positives with PCR.

4. Structural analysis of the major immediate early gene of human cytomegalovirus.

5. Prevention of transfusion-acquired cytomegalovirus infections in newborn infants.

1. Quantitative analysis of latent human cytomegalovirus.

2. Human cytomegalovirus latency-associated protein pORF94 is dispensable for productive and latent infection.

3. Detection of cytomegalovirus in urine samples by an enzyme-linked immunosorbent assay using a monoclonal antibody against the viral 150-kilodalton protein.

4. Experimental human cytomegalovirus latency in CD14+ monocytes.

5. Human cytomegalovirus replicates abortively in polymorphonuclear leukocytes after transfer from infected endothelial cells via transient microfusion events.

6. Cytomegalovirus remains latent in a common precursor of dendritic and myeloid cells.

7. Widespread presence of cytomegalovirus DNA in tissues of healthy trauma victims.

8. Cytomegalovirus in blood from blood donors.

9. Long-term oral therapy with valganciclovir in patients with Posner-Schlossman syndrome.

10. Reactivation of porcine cytomegalovirus through allogeneic stimulation.